Oncothyreon | THE "NEW" PROSTATE CANCER INFOLINK

Follow The "New" Prostate Cancer InfoLink news blog on TWITTER or FACEBOOK.
The "New" Prostate Cancer InfoLink has been developed to become a primary source of accurate, current, and topical information about prostate cancer for patients and their families.
A service of

Prostate Cancer International.
Awards
Other PCI web sites

El Cáncer de Próstata Latinoamérica
Prostate Cancer Africa
Prostate Cancer Caribbean
Solidarité Prostate InfoLink
Copyright © 2008-18 Prostate Cancer International, Inc.

Oncothyreon enrolls first patient in Phase II trial of PX-866 for CRPC

Posted on September 12, 2011 by Sitemaster

Oncothyreon, Inc. has announced initiation of a Phase II clinical trial of the company’s investigational agent PX-866 in the treatment of men with chemotherapy-naïve, recurrent or metastatic, castration-resistant prostate cancer (CRPC). … READ MORE …

Filed under: Drugs in development, Management | Tagged: castration-resistant, inhibitor, kinase, metastatic, Oncothyreon, PX-866 | Leave a comment »

THE "NEW" PROSTATE CANCER INFOLINK

A service of

Awards

Other PCI web sites

Oncothyreon enrolls first patient in Phase II trial of PX-866 for CRPC

Disclaimer

Hot Posts …

… and Archives